TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
批准号:
9005628
负责人:
Jerzy W Kupiec-Weglinski
金额:
$34.65万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-01-01 至 2020-12-31
关键词:
AblationAddressAdhesionsAdoptive TransferAffectAntioxidantsAutophagocytosisBiologicalBone MarrowCD4 Positive T LymphocytesCell Culture TechniquesCell DeathCellsCessation of lifeClinicalCoculture TechniquesCryopreservationCytoprotectionDataDevelopmentEndothelial CellsFoundationsGalactose Binding LectinGalectin 3HMGB1 ProteinHepaticHepatocyteHomeostasisHydrogen PeroxideITGAM geneImmuneImmune ToleranceImmunityImmunoglobulinsIn SituIn VitroInflammationInjuryIschemiaLabelLigandsLigationLiverLiver diseasesLiver neoplasmsLiver parenchymaMacrophage ActivationModelingMolecularMucinsMusOrganOrgan DonorOrgan TransplantationOutcomeOxidation-ReductionPathologyPathway interactionsPatientsPatternPhenotypePopulationProcessRegulationReperfusion InjuryReperfusion TherapyReportingResearchResistanceResponse ElementsSentinelSignal PathwaySignal TransductionStagingSterilityStressSystemT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsTLR4 geneTestingTherapeutic InterventionTimeTissuesTransplant RecipientsWarm Ischemiaallograft rejectionclinically relevantconditioningimprovedin vivoliver ischemialiver transplantationmacrophagemouse modelnovelnovel strategiesnovel therapeuticsp65preconditioningprogramspublic health relevancereceptorresearch studyresponsesuccesstargeted treatmenttrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) remains the primary obstacle limiting the success of orthotopic liver transplantation (OLT) in patients with end-stage liver disease and those with tumors of hepatic origin. Our group has pioneered the concept that hepatic IRI, an exogenous Ag-independent, innate immune-dominated sterile inflammation response, requires activated CD4+ T cells to facilitate tissue damage. T cell Immunoglobulin Mucin (TIM)-3 receptor has been recognized as a central regulator of T cell activation in a number of auto- / allo-immunity pathologies and organ transplantation. We reported that disruption of TIM-3 - Gal-9 pathway exacerbated hepatocellular injury in mouse livers subjected to warm IR. Then, we found that recipient CD4+TIM-3+ cells conferred resistance against liver IRI, suggesting a discrete host T cell subset should be spared while applying T cell-targeted therapy in transplant recipients. This proposal explores the function of TIM-3 signaling pathway in the mechanism of hepatic IRI in a clinically relevant mouse model of extended cold storage followed by orthotopic liver transplantation (OLT). First, we found that stressed hepatocytes express Gal-9 and HMGB1, i.e., known TIM-3 ligands. Second, we discovered robust expression of TIM-3 on activated liver endothelial cells (LEC). These preliminary data have led us to a central hypothesis that negative regulation between hepatocellular-derived Gal-9/HMGB1 and TIM-3 expressed on host circulating CD4+ T cells/graft LEC is essential to control tissue injury, and impose cytoprotective phenotype in IR-stressed OLT. Two interlocked specific aims will test this hypothesis: Aim 1: Define molecular mechanisms by which hepatocyte Gal-9 - CD4+ T cell TIM-3 negative regulation confers OLT resistance against IR stress. Aim 1.1. Hypothesis: Gal-9 - TIM-3 signaling triggers anti-oxidant response in which amplified Nrf2 activity represses macrophage NFB/inflammation responses. Aim 1.2. Hypothesis: Gal-9 - TIM-3 signaling enhances hepatocyte autophagy via Keap1/Nrf2 redox network. Aim 2: Define molecular mechanisms by which hepatocellular HMGB1 - endothelial TIM-3 negative regulation alleviates IRI in OLT. Aim 2.1. Hypothesis: HMGB1 conditioning prior to IR insult triggers activation of liver endothelial TIM-3 to repress macrophage trafficking and sequestration in OLT. Aim 2.2. Hypothesis: Hepatocellular HMGB1 - endothelial TIM-3 signaling promotes LEC protective phenotype. These studies will discern novel mechanisms at the innate-adaptive immune interface, which control organ damage/promote homeostasis in IR-stressed OLT; and should contribute to the development of new therapies to increase donor organ pool and improve clinical outcomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10101174
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10685284
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10472636
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10268216
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immune Interface in Liver Ischemia-Reperfusion Injury
-
批准号:9975698
-
项目类别:
-
资助金额:$38.23万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9359428
-
项目类别:
-
资助金额:$168.58万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10328210
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10622462
-
项目类别:
-
资助金额:$54.09万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:9975689
-
项目类别:
-
资助金额:$12.17万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9975685
-
项目类别:
-
资助金额:$167.45万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9750602
-
项目类别:
-
资助金额:$168.08万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10622453
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10622451
-
项目类别:
-
资助金额:$194.91万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10328213
-
项目类别:
-
资助金额:$53.42万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10328209
-
项目类别:
-
资助金额:$194.13万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9198218
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:9029320
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:8895119
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HO1 ANDTLR4 IN LIVER ISCHEMIA/REPERFUSION INJURY IN TRANSPLANT RECIPIENTS
-
批准号:7808751
-
项目类别:
-
资助金额:$61.6万
-
财政年份:2009
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HEME OXYGENASE-1 IN HEPATIC ISCHEMIA/REPERFUSION INJURY
-
批准号:6847822
-
项目类别:
-
资助金额:$33.55万
-
财政年份:2003
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
海外基金